.svg){kind=small}
Jun-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
In June 2026, Indo Cannabis concentrated 48.82% of sales in Capsules with a year-over-year decline of 47.16% and a month-over-month dip of 6.76%, while Topical expanded to 35.63% share with 14.11% YoY growth and 5.97% MoM increase; Vapor Pens held 15.55% share with 96.33% YoY growth but fell 18.96% MoM. Average price dropped 7.46% YoY to $27.44 as Capsules and Topical clustered around $27.09–$27.25 and Vapor Pens sat higher at $28.94, indicating a mix shift toward lower-priced formats alongside a volatile pen segment. The pattern implies Indo Cannabis is relying on Capsules scale despite contraction while Topical and Vapor Pens are becoming the swing factors for month-to-month momentum.
Holding rank 2 in Capsules in Nevada alongside a 47.16% YoY decline in that category and a 6.76% MoM drop suggests defensible placement but eroding throughput, while Topical’s 14.11% YoY and 5.97% MoM gains point to a counter-cyclical buffer within the portfolio. With overall brand sales down 23.98% YoY and a 24‑month change of -6.13%, the widening split between a contracting Capsules core and expanding, price-adjacent Topical and high-variance Vapor Pens implies Indo Cannabis is migrating from a single-category anchor toward a barbell positioning that trades steady rank for diversified, timing-sensitive growth levers.
Competitive Landscape
Indo Cannabis sits at rank #2 in NV Capsules in June 2026, up 1 position year over year, after previously peaking at #1 in November 2025 and holding #2 over the last three months; this contrasts with Level at #1, which fell 1 position YoY to #2 last year while its sales declined 25.8%, and Cannavative at #3, which rose 1 position YoY to #3 alongside a 63.6% sales increase. With Indo Cannabis trailing the category lead at #2 yet improving its YoY rank by 1 and maintaining a stable #2 quarter-to-date, the trajectory implies a plateau just below leadership rather than a re-acceleration back to its #1 peak.
Notable Products
Maxtabs - THC Capsules 10-Pack (100mg) posted the steepest decline at -38.5% and slipped to rank 5, while CBN/CBD/THC 1:1:1 Slow Bars Tablets 5-Pack (200mg CBD, 200mg CBN, 200mg THC) fell -29.4% to rank 6, indicating a pullback in multi-pack Capsules even as IndoPuff- Blueberry Punch Distillate Disposable (1g) rose 10.0% to rank 7. Topicals held the top two ranks with CBD/CBN/THC 4:4:1 Jungle Stick IndoBalm (400mg CBD, 400mg CBN, 100mg THC) up 7.1% at rank 1 and CBD/THC/CBN 4:4:1 Jungle Stick Balm (400mg CBD, 400mg THC, 100mg CBN) down 0.4% at rank 2, concentrating leadership away from Capsules where three SKUs in the top ten posted double-digit declines or low growth. Within Capsules, THC Maxtabs 2-Pack (200mg) gained 18.9% to rank 3 while Glow Bars Tablets 5-Pack (200mg) rose 12.9% to rank 8, but the offset was insufficient to counter the 10-Pack contraction, totaling $16,967 in June 2026 sales for the declining pack size. The pattern implies Indo Cannabis is tilting toward smaller-dose or convenience formats and Topicals-led traffic, suggesting portfolio adjustments should favor compact Capsule packs and maintain investment in Topicals while de-emphasizing bulk Tablet formats.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
